Advanced Code injection

Ontario Industry Updates

KA Imaging Prepares to Enter the Health Care Market With Revolutionary Digital X-Ray Detector

Canadian manufacturer KA Imaging has managed to overcome the challenge of having soft-tissue differentiation and single exposure featured in the same digital X-ray detector. The company plans to present Reveal™ to the Health Care market next year. Reveal™ is the world’s first portable digital detector capable of separating different energy levels.

Synaptive Announces Co-Marketing Collaboration with Stryker, Expansion Into Spine Market

Synaptive Medical, a leader in automation and robotics, announced today a strategic commercial expansion into the spinal surgery market. As part of this expansion, Synaptive is also announcing a co-marketing collaboration with Stryker’s Advanced Guidance Technologies business for the company’s robotically controlled digital microscope, Modus V™.

KA Imaging announced as one of 10 companies in this year’s Lazaridis ScaleUp Program

The Lazaridis Institute for the Management of Technology Enterprises has selected 10 of the country’s most promising technology companies to participate in the fifth cohort of the Lazaridis ScaleUp Program. The institute, housed in Wilfrid Laurier University’s Lazaridis School of Business and Economics, supports Canada’s tech sector through research and programming focused on growth and innovation. Its ScaleUp Program helps companies grow globally through mentorship, programming, and access to a global network of experts.

Apply for the Genomic Applications Partnership Program (GAPP)

Ontario Genomics is pleased to announce that a new round of Genome Canada’s Genomic Applications Partnership Program (GAPP) is now open (Round 18). The program provides a unique opportunity for Receptor organizations to collaborate with an ’omics researcher, and to leverage their R&D investments with public funding.

Application deadline: October 28, 2019

Click here to learn more.

Interface Biologics Announces Sale of Surface Modification Business to Evonik

Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the sale of its surface modification business to Evonik, a German based specialty chemical company with revenues in excess of €13 billion in 2018.

Click here for more information